A boxed warning has been added to the label for Ozempic (semaglutide), effective 2026-07-30. This significant label revision highlights the RISK OF THYROID C-CELL TUMORS. The warning explicitly states that semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors in rodents at clinically relevant exposures. It is currently unknown whether Ozempic causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans.
What this means
The inclusion of a boxed warning on the Ozempic label carries significant implications for prescribing practices and patient education. Healthcare providers must now counsel patients about the observed risk of thyroid C-cell tumors in rodent studies and the current uncertainty regarding this risk in humans. This warning, effective 2026-07-30, emphasizes the need for careful consideration, particularly in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in those with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). While the direct causal link in humans remains unestablished, the FDA's decision to add this warning reflects a commitment to ensuring that all potential risks, even those extrapolated from animal data, are prominently communicated to safeguard public health. Patients should be advised to report symptoms such as a mass in the neck, dysphagia, dyspnea, or persistent hoarseness, which could be indicative of thyroid tumors.
Source
This information is based on an FDA label revision for Ozempic (semaglutide), effective 2026-07-30. The full details of the label change are available on dailymed.nlm.nih.gov.